Three-year dispensing patterns with long-acting inhaled drugs in COPD: A database analysis - 02/08/11
, Myrthe van Herk-Sukel a, Rupert Gale b, Jan-Willem Lammers c, Ron Herings a, d
Corresponding author. Tel.: +31 302345 162; fax: +31 302345 568.Summary |
Background |
Long-acting muscarinic antagonists (LAMA), long-acting β2-agonists (LABA) and fixed dose combinations (FDC) of inhaled corticosteroids (ICS) and LABA are used as inhaled maintenance therapies for COPD.
Objective |
To estimate persistence rates from dispensing patterns of long-acting inhaled drugs for COPD.
Methods |
From the PHARMO-database, COPD patients starting LAMA, LABA or LABA-ICS FDC between 2002 and 2006 were selected. Persistence with the initial as well as with any long-acting inhaled drug was determined, defined as time between start and stop of initial/any therapy, allowing ≤60-days gaps between refills. For patients who did not continue to receive dispensings of the initial therapy for at least one year, the first change in therapy was determined.
Results |
The study included 2201 LAMA, 1201 LABA and 4146 LABA-ICS FDC users. Persistence rates with initial therapy alone at 1, 2, and 3 years were 25%, 14%, 8% for LAMA, 21%, 10%, 6% for LABA and 27%, 14%, 8% for LABA-ICS FDC. Of patients who did not persist with LAMA alone for one year, 15% added and 13% switched therapy (both mostly LABA-ICS FDC). Of patients not persisting with LABA alone, 9% added therapy (mostly LAMA) and 31% switched therapy (mostly to LABA-ICS FDC). In patients not persisting with LABA-ICS FDC, add-on and switch occurred equally frequent (11%, mostly LAMA). Persistence rates with any long-acting drug at 1, 2 and 3 years were 36%, 23% and 17% respectively.
Conclusion |
Persistence with the initial as well as with any long-acting inhaled drug in COPD is low, with a substantial proportion of patients changing therapy.
Le texte complet de cet article est disponible en PDF.Keywords : COPD, Long-acting inhaled drug, Persistence, Treatment pattern
Plan
Vol 105 - N° 2
P. 259-265 - février 2011 Retour au numéro
Article précédent
- Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD
- Andre-Bernard Tonnel, Isabelle Tillie-Leblond, Valerie Attali, Zola Bavelele, Olivier Lagrange
- A longitudinal study of serial BODE indices in predicting mortality and readmissions for COPD
- Fanny W.S. Ko, Wilson Tam, Alvin H.M. Tung, Jenny Ngai, Susanna S.S. Ng, Kenneth Lai, Ka-Fai Au, David S.C. Hui
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?